Latest Breaking News On - Driven cancers - Page 1 : comparemela.com

Nested Therapeutics Announces Oral Presentation of Preclinical Data for NST-628, a Novel, Fully Brain-Penetrant, Pan-RAF/MEK Molecular Glue, at the 2024 AACR Annual Meeting

/PRNewswire/ Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today.

United statesKlaus hoeflichAmerican association for cancer researchCancer discoveryAmerican associationCancer researchFully brain penetrantMolecular glueDriven cancersNested therapeutics inc

Nested Therapeutics Announces Oral Presentation of Preclinical Data for NST-628, a Novel, Fully Brain-Penetrant, Pan-RAF/MEK Molecular Glue, at the 2024 AACR Annual Meeting

Concurrent publication in the journal Cancer Discovery highlights NST-628 s differentiated mechanism and preclinical activity across diverse KRAS-, NRAS-, and BRAF-driven tumors

United statesKlaus hoeflichTherapeutics incAmerican association for cancer researchCancer discoveryAmerican associationCancer researchFully brain penetrantMolecular glueDriven cancersNested therapeutics

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nate liabraatenDan calkinsElisa buffingtonBrian stuglikChugai pharmaceutical co ltdDrug administrationBalance sheet to deliver on development milestonesExchange commissionSecura bio incCorporate communicationsRaf and mek programOxford financeDefactinib combination advancingRecurrent low grade serous ovarian cancerPositive dataPlanned interim analysis